Home blood testing: when a result is useful

Home blood collection can make an appropriate test easier to obtain. Its value depends on the exact test, how the sample travels to the laboratory, and what the result will change. A subscription does not establish how often a person needs testing. Start with the decision: what would you or your clinician do differently if this value changed? [1] [13]

Longevitytech.fund — supporting longevity research

Longevitytech.fund is proud of its early backing for SiPhox’s work on accessible blood-testing technology. Intel Capital’s July 19, 2023 financing announcement named Longevity Tech Fund among SiPhox’s seed investors. The company’s work addresses a practical question: when can easier sample collection produce a clinically useful result? [12]

What has been shown?

• Selected routine tests can work with mailed capillary samples. A 2026 German study found strong agreement for A1C (a measure of average glucose), creatinine and cholesterol measurements after postal transport averaging about 40 hours. Collection support and incomplete samples were important parts of the result. [14]

• Success does not transfer automatically to other assays. Studies of research protein panels and different processing or temperature conditions have found less favorable results. [3] [15]

• Evidence that would strengthen a particular service would show acceptable agreement, usable-sample rates and stability for its actual collection kit, laboratory methods and shipping conditions, followed by a useful plan for the result.

Does the test happen at home, or only the collection?

A collection device is not necessarily a diagnostic analyzer. A “five-minute test” may mean five minutes collecting blood, followed by days before the laboratory report. FDA guidance recognizes useful home tests, including glucose monitoring, while emphasizing instructions and interpretation alongside medical history and other clinical information. [1]

Accuracy belongs to the particular assay

An assay is the method used to measure a substance. Capillary blood comes from small vessels near the skin; venous blood comes from a vein. They are not interchangeable for every test. Dried blood spots, liquid whole blood, serum and plasma are also different sample materials. Serum and plasma are liquid portions of blood prepared in different ways. Validation needs to cover the combination actually offered. [2] [3] [14]

Four studies illustrate what this means in practice.

Routine chemistry collected by professionals

A 2025 study compared four upper-arm collection methods and a fingerstick with venous sampling in 41 healthy adults. Several measurements, including cholesterol and C-reactive protein, showed strong agreement. Capillary creatinine, however, read about 8% lower on average, and carbon dioxide performed less well. Trained professionals collected the samples under controlled conditions. This was not a trial of people collecting and mailing blood unaided, and healthy participants did not cover the full range of values seen in clinical care. [2]

Selected routine tests sent by ordinary mail

A June 2026 study in two German general practices analyzed 105 patients. Participants used Tasso+ with help available, and staff prepared the mailing packages. A1C, creatinine and cholesterol measurements agreed strongly with venous results after postal transport averaging about 40 hours. [14]

Not every collected sample supplied every result: paired analyses included 100 A1C, 82 creatinine, 85 LDL cholesterol, and 86 measurements each of HDL and total cholesterol. The paper reported that about 22% of samples lacked enough blood for complete metabolic analyses. Those details matter when judging convenience: accurate results from usable samples and the chance of obtaining a complete panel are different questions. The study supports this workflow, with assistance and packaging, rather than every unsupervised home setting or postal system. [14]

A research protein panel after delayed processing

A 2024 pilot involved 20 volunteers using Tasso+ collection under supervision, with assistance available. Researchers held samples chilled for 24 or 48 hours before processing, to simulate transport, and measured inflammatory proteins with an Olink research panel. Of 230 proteins retained after quality filtering, only 26 met the researchers’ combined correlation and variation criteria under both storage conditions. [3]

This result limits the transfer of that research panel to that remote-collection method. It does not make all routine home blood tests inaccurate. The positive postal study and the less favorable protein study used different assays, processing methods and acceptance criteria. Neither tested SiPhox’s complete service. [3] [14]

A simulated shipping delay

A May 2026 study tested a 48-hour processing delay in relatively healthy volunteers. Potassium, bicarbonate and glucose differed materially from venous results, while several other measurements stayed within the study’s acceptance limits. More extreme temperatures caused additional problems. These findings describe a particular protocol and small groups for individual comparisons, not a universal 48-hour shipping deadline. [15]

Similar rankings can hide important errors

Two methods can have a high correlation—ranking people in much the same order—while one consistently reads higher. For a medical decision, ask about the average difference, the range of differences in individuals, and accuracy near the value that would change care. Failed, insufficient or damaged samples also count when assessing a service; a graph of successful samples cannot describe the whole experience. [2] [3] [14] [15]

Good shipping practice is just as specific. Stability of one protein under one protocol does not establish stability of another protein or tolerance of a hotter journey. A laboratory cannot undo every collection or transport problem. Too little blood, an unsuitable container, delayed processing or damaged blood cells can affect what can be measured. [2] [3] [15]

Make the sample’s journey part of the plan

Follow the particular kit’s instructions for preparation, collection volume, packaging, storage and dispatch. Check its expiration date and any restrictions on shipping days. Contact the provider if collection went wrong or transit exceeded its permitted conditions. Do not substitute different storage conditions or assume a partly completed kit will be adequate. FDA home-test guidance specifically emphasizes sample amounts, timing, storage and interfering factors. [1]

The provider should explain what happens to an unsuccessful sample: rejection, recollection or a report explaining the limitation. A missing result is not a normal result.

For comparisons over time, keep the original laboratory report, units, method when available, and preparation details. Note illness, changes in medicines or supplements, and collection conditions. Using the same laboratory where practical can make comparisons easier, although it does not eliminate natural biological variation. [13]

SiPhox’s mail-in service and research analyzer are different products

On September 22, 2026, SiPhox Health described upper-arm collection using its EasyDraw kit, followed by laboratory analysis, with mail-in testing fulfilled by third parties. Its separate SiPhox Home light-based analyzer page labeled that device investigational and for research use only. The commercial mail-in service and the proposed home analyzer have different evidence and regulatory questions. [9] [10]

SiPhox states that it uses CLIA-certified and CAP-accredited laboratories and validates assays against venous draws. Those company statements do not, by themselves, establish every current assay’s agreement in individuals, failed-sample rate or shipping stability. Ask for evidence tied to the actual kit, laboratory and test menu. A general explanation of why laboratories differ does not answer those questions. [9] [11]

Version matters, too. A March 2024 company article describes finger-prick dried-card collection; the September 2026 main site describes upper-arm collection. Instructions or validation for one format should not be applied to the other. SiPhox also describes its service as wellness-only, not designed to diagnose, prevent or treat disease. That limit matters when interpreting disease-risk categories on a dashboard. [9] [11]

A mail-in service being available does not establish clearance of a home analyzer. An early analyzer demonstration likewise does not validate all assays in the mail-in service. [10]

What US certification and clearance actually cover

CLIA certification concerns laboratory quality requirements. CMS describes its purpose as supporting accurate, reliable and timely testing. It is different from FDA review of a specific consumer test’s claims, and from evidence that a broad panel is medically useful for an individual. [6] [8]

Device clearance also has a defined scope. On August 12, 2022, the FDA cleared Tasso+ as a single-use blood-lancing device for obtaining small capillary whole-blood samples. That FDA decision specifies prescription use. Its collection function does not establish the accuracy of every later assay or the benefit of repeated screening. It also does not establish that a differently named collection kit is the same device. [7]

The FDA distinguishes analytical validity—measuring the substance correctly—from clinical validity—how the measurement relates to the claimed health state. Some consumer tests receive FDA review and others do not, depending on their purpose and pathway. Look for the exact test and intended use. US regulatory facts apply to that jurisdiction. [8]

How often should you repeat a test?

Frequency should follow the clinical purpose and the time needed for a meaningful change. There is no useful universal interval for a collection of unrelated biomarkers.

• A person using prescribed glucose monitoring may need frequent measurements to guide a diabetes plan. That is a defined use with an action attached to the result. [1]

• A1C reflects average glucose over roughly three months. NIDDK describes testing at least twice a year for people with diabetes, with more frequent checks when treatment goals are not met. This is diabetes-management guidance, not a schedule for broad panels in healthy adults. A1C and an immediate glucose reading answer different questions. [4]

• An unexpected value may need targeted confirmation or prompt clinical assessment. The response depends on symptoms, the size of the change, prior results and possible temporary influences or error. Another complete mail-in panel may be less useful than an appropriate venous test directed at the actual question. [1] [13]

Before repeating, agree which result would trigger action and who will review it. Extra measurements cannot resolve a question that the test was not designed to answer.

A noisy age estimate does not set a blood-testing schedule

A 2026 Aging Cell analysis examined 18 measures of aging based on DNA methylation—chemical markings on DNA. It distinguished repeated laboratory measurements of the same sample from separate samples collected over short periods under different conditions. Getting similar results when a laboratory retested the same sample did not reliably predict stable scores when people provided repeat samples. The analysis also had small, often young study populations, limited control groups and uncertainty about longer-term patterns. [5]

This supports careful interpretation of changing epigenetic age estimates. It did not test whether monthly cholesterol, hormone, vitamin or inflammation panels improve care, or whether frequent age-score testing changes a care decision. Those are different assays and clinical questions. [5]

Averaging appropriately repeated measurements can reduce some random variation. It cannot remove consistent over- or underestimation, repair unsuitable sample handling or give an otherwise irrelevant test a useful purpose.

How Healthy Longevity Clinic experts evaluate the evidence

For someone who wants to track a meaningful change, the first distinction is between a change in health and a change in measurement. Suppose a creatinine result falls after switching from venous sampling to home collection. The roughly 8% lower capillary readings in one study show why the methods need checking before treating that difference as an improvement. The favorable mailed-sample creatinine results in another study also show why the answer must be specific to the workflow. Neither study tells us how every commercial kit performs. [2] [14]

The second question is whether repeating the value can change care. A1C monitoring in established diabetes has a purpose and a timescale. Repeatedly measuring an unrelated wellness panel needs its own reason. An unexplained flag should lead to interpretation and, when appropriate, targeted confirmation; it should not automatically become a diagnosis or a supplement purchase. [1] [4] [13]

A useful consultation therefore connects the exact assay and shipping protocol to an agreed next step. Evidence that would improve confidence in a home service would include reliable results near decision thresholds, a clear count of failed samples, and a demonstration that easier access helps people complete appropriate testing and follow-up. More measurements alone do not establish that benefit.

A flag is a reason to interpret, not a diagnosis

A value outside a laboratory reference range can occur in a healthy person; a value inside it does not rule out every problem. Methods, units and reference ranges differ between laboratories. If a dashboard uses an “optimal” category, compare it with the original report and ask what decision that category supports. [13]

Larger panels create more opportunities for unexplained flags. Reacting to every small change can prompt further tests, referrals, supplements, expense and worry. A testing plan helps distinguish a finding needing action from one needing confirmation or observation. Keep following an existing treatment plan; do not change medicines solely because of an unreviewed wellness dashboard. [1] [13]

Three questions for a consultation

1. Has this exact test been compared with the appropriate venous method using this collection kit and these shipping conditions, including values near the point that would change my care?

2. What would a changed result lead us to do, when is repeating it meaningful, and could a targeted test answer the question?

3. Who reviews important abnormal results, and what happens if my sample is late, insufficient or unreportable?

Common questions

Can a mailed blood sample give an accurate result?

Yes, for a validated combination of sample, handling and assay. The 2026 German study found strong agreement for selected routine measurements after ordinary postal transport. Assistance, staff packaging and incomplete sample volumes remain part of that finding. [14]

Does a CLIA-certified laboratory mean the whole panel is FDA approved?

No. CLIA addresses laboratory quality requirements. FDA review of a particular test and evidence that testing benefits you are separate questions. [6] [8]

Should I repeat everything monthly to see a trend?

No general monthly schedule follows from these studies. Choose the test and interval for the decision. A1C monitoring in diabetes, an unexpected result needing confirmation and a research age estimate have different purposes. [1] [4] [5]

What if one result is missing?

Ask whether the sample was insufficient, unsuitable or otherwise unreportable, and what the provider recommends next. A missing value cannot be interpreted as a measured normal result. Follow the kit’s instructions and the clinical plan. [1]